Table 3.

Application of the humanized mouse model for immunotherapy

Disease	Tumor origin	Immune reconstitution	Therapy	Reference
Leukemia	CDX	HSCs	WT-1 TCR-T therapy	[86]
Melanoma	CDX	HSCs, FT, FL	F5 TCR-T therapy	[88]
B-ALL	PDX	HSCs, FT, FL	Anti-CD19 CAR-T therapy	[90]
Pancreatic cancer	CDX	PBMCs	PSCA CAR-T therapy	[92]
Gastric cancer	CDX	PBMCs	chA21-4-1BBz CAR-T therapy	[93]
NSCLC	CDX	PBMCs	EGFR CAR-T therapy	[94]
TNBC	PDX	HSCs	Anti-PD-1 therapy	[101]
NSCLC	CDX&PDX	PBMCs, HSCs	Anti-PD-1/PD-L1 therapy	[102]
Colorectal cancer	PDX	HSCs	Anti-PD-1 therapy	[103]
Osteosarcoma	CDX	PBMCs	Anti-PD-1 therapy	[100]
Lymphoma	CDX	HSCs, FT, FL	Anti-PD-1/CTLA-4 therapy	[104]
Ovarian cancer	PDX	TILs	Anti-PD-1 therapy	[105]
HCC	PDX	HSCs	Anti-PD-1/CTLA-4 therapy	[9]
Mesothelioma	CDX	PBMCs	CAR-T + anti-PD-1 therapy	[106]